Home › Compare › ADCOF vs ABBV
ADCOF yields 1834.86% · ABBV yields 3.06%● Live data
📍 ADCOF pulled ahead of the other in Year 1
Combined, ADCOF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ADCOF + ABBV for your $10,000?
Adcore Inc. operates as an e-commerce advertising management and automation platform in the Asia-Pacific, Europe, the Middle East, Africa, and North America. The company offers smart algorithm powered automation tools for digital advertisers to enhance return on advertising investments, and scale their digital campaigns. Its product portfolio includes Feeditor that offers online shopping automation capabilities to advertisers; Views, a search engine marketing (SEM) solution used for campaign creation, intelligent bid management, SEM optimization, and reports; SEMDOC, an account auditing tool, which measures and analyzes 52 metrics; Effortless Marketing, a marketing solution for campaign creation and performance tracking; and Amphy, a 24/7 live online learning marketplace. The company serves enterprise companies, and small- and medium-sized businesses. Adcore Inc. was founded in 2005 and is headquartered in Tel Aviv, Israel.
Full ADCOF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.